How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2021.1982383
Abstract: ABSTRACT Introduction JAK-inhibitors have emerged as a new treatment option for rheumatoid arthritis, with five molecules currently available in different parts of the world: tofacitinib, baricitinib, upadacitinib, peficitinib, and filgotinib. These molecules have been the… read more here.
Keywords: trials real; world; world studies; real world ... See more keywords
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Haematology"
DOI: 10.1111/bjh.19627
Abstract: The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide‐refractory patients, which may limit the efficacy of subsequent lines of treatment (LOT). This systematic literature review (January 2008–October… read more here.
Keywords: multiple myeloma; refractory; real world; lenalidomide refractory ... See more keywords
Editorial: From randomized clinical trials to real-world data and big data sciences: Generating evidence-based medicine for value in western and herbal medicines
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2023.1129399
Abstract: © 2023 Xiong, Lv, Jiang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided… read more here.
Keywords: editorial randomized; clinical trials; trials real; randomized clinical ... See more keywords
Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data
Sign Up to like & getrecommendations! Published in 2025 at "Cancers"
DOI: 10.3390/cancers17050735
Abstract: Simple Summary Janus kinase inhibitors are effective oral therapies for inflammatory bowel disease. While these drugs improve treatment options, safety concerns remain, particularly regarding cardiovascular and infectious risks, especially in patients with existing risk factors.… read more here.
Keywords: cancer risk; real world; risk; trials real ... See more keywords